Hormone Receptor (HR / ESR1) Drug Discovery Landscape & Assay Solutions
- By admin
- 09 Oct 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Endocrine-Resistant Breast Cancer Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Hormone Receptor (HR / ESR1) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HR / ESR1 Wild Type & Mutant Recombinant Proteins (Y537S, D538G) High purity (>95%), Endotoxin Controlled, Sequence Verified. Ideal for SPR, FP, and TR-FRET binding assays. |
View HR Products |
| Gene Delivery | HR / ESR1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation, nuclear translocation, and reporter gene assays. |
View HR Products |
| Benchmark Ab | Anti-HR Recombinant Antibody (Biosimilar Control) Recombinant positive control matching clinical benchmark sequence. |
View HR Products |
| Validator | HR / ESR1 siRNA Set Target-specific knockdown verification for functional assay validation. |
View HR Products |
| Related Target A | CDK4 Synergistic cell cycle mediator; standard combination therapy partner in HR+ breast cancer. |
View CDK4 Products |
| Related Target B | Cereblon (CRBN) Key E3 ligase partner for Estrogen Receptor-targeting PROTACs (e.g., ARV-471). |
View CRBN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Targeting Endocrine Resistance Mutations | Y537S and D538G mutant proteins strictly sequence-verified with high purity (>95%) for mutant-selective screening. |
| Subfamily / Off-target Screening | Homolog panel (including PR, AR, GR) available with precise mass spectrometry verification. |
| Lack of Controls | Clinical benchmark antibodies (biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for target knockdown specificity checks. |
Live HR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Hormone Receptor (HR / ESR1) therapeutics is intensifying, with major players shifting focus from traditional Selective Estrogen Receptor Modulators (SERMs) to next-generation Selective Estrogen Receptor Degraders (SERDs), PROTACs, and Complete Estrogen Receptor Antagonists (CERANs). As first-generation oral SERDs reach the clinic, the next wave of R&D is targeting acquired resistance mutations in the ligand-binding domain (LBD), specifically Y537S and D538G, which drive ligand-independent receptor activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Oral SERD | AstraZeneca, Menarini, Roche | ER+/HER2- Metastatic Breast Cancer | Mutant LBD binding assays (Need mutant recombinant proteins) |
| PROTAC (Degrader) | Arvinas, Pfizer | Endocrine-Resistant Breast Cancer | Ternary complex formation & degradation kinetics (Need CRBN/VHL & HR proteins) |
| CERAN | Eli Lilly | Advanced Solid Tumors | Transcription inhibition assays (Need Lentivirus for stable reporter lines) |